Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1116_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
20 Мб
Скачать
How to Manage Sleeve Complications Through Endoscopy: Gastroesophageal Reflux Disease
Thomas R. McCarty and Christopher C. Thompson

1 Introduction

The development of gastroesophageal reflux disease (GERD) and heartburn asso­ciated symptoms is quite common among patients following sleeve gastrectomy. New-onset GERD or worsening GERD among individuals with pre-existing heart­burn symptoms is a well-known complication of laparoscopic sleeve gastrectomy. Although GERD symptoms improve for the vast majority of patients (87–100%) following Roux-en-Y gastric bypass, sleeve gastrectomy has been shown to result in an increase in GERD for patients post-procedure [15]. As such, less invasive endoscopic treatments are needed to target this specific population. In this chapter, we will review the mechanisms that predispose to GERD after sleeve gastrectomy, incidence of GERD post-procedure, screening recommendations, as well as proper diagnosis and treatment. Additionally, we review three endoscopic interventions that may provide improvement for patients with GERD after sleeve gastrectomy.

2 Mechanisms of GERD Post-Sleeve Gastrectomy

Many potential theories for the development of GERD after sleeve gastrec­tomy have been proposed [6]. Given the nature of the gastric sleeve, there is a decrease in gastric compliance, resulting in a rigid stiff stomach with little abil­ity for accommodation [7]. This likely leads to an increased intraluminal pressure,
T. R. McCarty · C. C. Thompson (*) Brigham and Women’s Hospital, Boston, USA e-mail: CCTHOMPSON@bwh.harvard.edu
T. R. McCarty e-mail: trmccarty@bwh.harvard.edu
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021 S. Al-Sabah et al. (eds.), Laparoscopic Sleeve Gastrectomy,
https://doi.org/10.1007/978-3-030-57373-7_47
499
T. R. McCarty and C. C. Thompson500
thereby increasing regurgitation or reflux of stomach contents into the esophagus with an intact pylorus. Additionally, laparoscopic sleeve gastrectomy results in a lower esophageal sphincter (LES) pressure and shortens the abdominal length of the esophagus [8]. Other potential causes may be iatrogenic in nature and are related to overlooking the presence of hiatal hernias and general shape of the sleeve, including over-dilation of the proximal part of the sleeve to create a reser­voir which may increase GERD [9, 10].

3 Incidence of GERD After Sleeve Gastrectomy

A landmark study by Genco et al. found that sleeve gastrectomy was associated with a significant increase in erosive esophagitis and non-dysplastic Barrett’s esophagus with no correlation between patient-reported symptoms and endoscopic findings [11]. This key finding that symptoms may not correlate with endoscopic findings was critical to the realization that a large majority of post-sleeve gastrec­tomy patients may develop GERD-related sequalae even without overt symptoms. In a recent systematic review and meta-analysis of 46 studies and over 10,000 patients, 19% of patients developed worsening GERD post-sleeve gastrectomy with another 23% reporting de novo symptoms [12]. Similar to the previous study, the long-term prevalence of esophagitis and Barrett’s esophagus after sleeve gas­trectomy was 28% and 8%, respectively.

4 Screening Recommendations

This increased risk of new onset Barrett’s esophagus has been estimated to be 15–17% by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). As such, this society currently recommends a surveillance endoscopy after sleeve gastrectomy at 1, 3, and 5 years, then subsequently every 10 years—with more frequent surveillance needed and consideration of conversion to Roux-en-Y gastric bypass should patients develop non-dysplastic Barrett’s esophagus [13]. Yet, despite this recommendation, significant variability remains among surgeons and gastro­enterologists with respect to screening for GERD and de novo Barrett’s esophagus post-sleeve gastrectomy. Furthermore, beyond traditional pharmacologic therapies, including proton pump inhibitors (PPIs), few endoscopic treatment options are avail­able for symptomatic and asymptomatic patients post-sleeve gastrectomy. In this review, we will highlight the important role of endoscopy in the management of GERD after sleeve gastrectomy and discuss several potential endoscopic treatments.

5 Role of Pharmacotherapy, Diagnosis, and Testing

For all patients with symptomatic GERD or evidence of esophagitis on upper endoscopy, standard PPI therapy (typically with starting dose of omeprazole 20 mg daily) is recommended. Although far less common compared to patients
How to Manage Sleeve Complications Through Endoscopy…
501
with Roux-en-Y anatomy, heartburn symptoms that fail to response to tradi­tional PPI therapy (classically higher dose PPI twice daily) should prompt inves­tigation for non-acid reflux. Due to the anatomy of Roux-en-Y gastric bypass, proper recognition of bile acid reflux with gastropathy or non-acid reflux as an alternative to GERD is important [14]. While the clinical diagnosis of GERD is based upon typical symptoms that respond to treatment with a PPI, more objec­tive measures including via 24 hour esophageal pH monitoring (diagnosed by having a pH < 4.0 and the length of time the esophagus is exposed to acid) may be helpful—especially for patients that may have no symptoms. Motility testing with pH and impedance testing along with manometry may also help to identify acid and non-acid reflux etiologies. Impedance testing is critical to differentiate acid versus non-acid reflux, thereby allowing proper identification of the underly­ing etiology. Esophageal manometry (i.e., motility testing) is also key as this may identify underlying functional disorders or explain difficult to control symptoms. Gastroenterologists and surgeons should collaborate in the care of these patients.
6 Anti-Reflux Mucosectomy (ARMS)
Given the significantly increased rate of de novo GERD and downstream conse­quences of possible Barrett’s esophagus, a need has been created for effective, sleeve-specific endoscopic GERD treatments. One such treatment for patients with refractory disease, and utilized as a potential alternative to surgical conversion to Roux-en-Y gastric bypass is the endoscopy procedure called anti-reflux mucosec­tomy (ARMS). This procedure involves endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of the gastroesophageal junction (GEJ) at the level of the gastric cardia from a retroflexed view [15]. Although this is a newer technique, this endoscopic procedure has really come to the forefront of endoscopic therapies in recent years. By performing EMR or ESD of the GEJ, this creates an area of fibrosis or scar formation potentially tightening the GEJ to reduce esophageal acid exposure and improve symptoms—similar to documented improvement in previous studies examining GERD symptoms after mucosal resec­tion for short-segment Barrett’s esophagus [1618].
The first case of the ARMS procedure was reported in a pilot study of 10 patients with normal gastric anatomy by Inoue and colleagues in 2014 [16]. In this study, importantly among patients without sleeve gastrectomy, DeMeester score, Hill classification (hiatal hernia), and time of esophageal acid exposure (pH < 4), all significantly improved post-ARMS procedure. Perhaps most importantly, symptoms improved across the board with PPI therapy completely discontinued for all 10 patients. Notably, stenosis did develop in 10 patients requiring endos­copy balloon dilation with control of symptoms. A subsequent case report by our group demonstrated application of this novel ARMS technique in a sleeve gastrec­tomy patient with a relatively narrow stomach with altered blood supply [15]. In this case, a 71-year-old woman with sleeve gastrectomy approximately 5 years prior developed worsening GERD post-procedure despite twice daily PPI therapy. Step-by-step procedure details are shown in Fig. 1 with significant resolution of
T. R. McCarty and C. C. Thompson502
Fig. 1 Antireflux mucosectomy (ARMS) procedure. (A) Pulsed argon plasma coagulation marks the 85% circumferential area of mucosa to be treated and the 15% of the circumference to be left untreated. (B and C) Gastroesophageal junction after 2 EMR procedures and after 8 EMR pro­cedures. (D) Retroflexed view after the completion of 10 resections, highlighting partial circum­ferential resection. (E and F) Follow-up EGD at 3 months, with the gastroesophageal junction in forward view and retroflexed view. (G) Timed barium swallow performed 3 months after ARMS with normal esophageal caliber, contour, distensibility, and prompt passage of contrast material
symptoms at 12 month follow-up. While more data among a population of patients with prior bariatric surgery is needed, ARMS may provide an alternative to surgi­cal conversion to Roux-en-Y gastric bypass. At this time, use of ARMS is limited to tertiary academic centers with high volume endobariatric expertise.

7 Radiofrequency Ablation

Use of radiofrequency ablation to the LES has been well studied as an effective treatment for GERD refractory to medical therapy [19]. Applied through a pro­cedure call Stretta (Mederi Therapeutics, Greenwich, CT, United States), which is a minimally invasive endoscopic procedure for the treatment of GERD, radi­ofrequency energy is applied to the LES and gastric cardia which results in local inflammation, collagen deposition, and muscular thickening to disrupt nerve fibers [20, 21]. This was approved by the United States Food and Drug Administration (FDA) in 2000. The device is a soft, flexible, bougie tip (20 French) that includes a balloon/basket with four 5.5 mm NiTi electrodes along with temperature and impedance monitoring—Fig. 2. The radiofrequency ablation procedure involves a balloon assembly with needle electrodes that are positioned
How to Manage Sleeve Complications Through Endoscopy…
Fig. 2 Representative images of Stretta device and procedure. Available at: https://www.restech.
com/solutions/stretta/
503
approximately one cm above the GEJ and deliver radiofrequency energy waves directly to the submucosa [22].
While effective, the vast majority of data is limited to non-sleeve gastrectomy patients. However, within the last few years, some literature has emerged regarding the safety and efficacy of radiofrequency ablation among a population of patients with sleeve gastrectomy. In a retrospective analysis of 15 patients at a single­center, Khidir and colleagues found that Stretta did not improve GERD symptoms in patients post-sleeve gastrectomy at follow-up of 6 months. Furthermore, adverse events occurred in 6.7% of patients and ranged from mild to severe and refractory symptoms. Overall, two-thirds of patients (n = 10) were not satisfied with the therapy despite 20% of patients being able to completely discontinue PPI therapy. Another small case series of a two patients undergoing Stretta after sleeve gastrectomy revealed positive results [24]. Given this limited data among patients with a history of sleeve gastrectomy, a multi-center clinical trial was underway (NCT02637713); however, this was terminated and results have not been released [25].

8 Transoral Incisionless Fundoplication (TIF)

The transoral incisionless fundoplication (TIF) procedure was first introduced in 2005 and later approved by the United States FDA in 2007. The procedure is performed using the the EsophyX device (EndoGastric Solutions, Redmond, Washington, USA) to reconfigure the GEJ to obtain a full-thickness esophageal valve from inside the gastric body, using serosa-to-serosa plications that include the muscle layers. The EsophyX device constructs an omega-shaped valve approx­imately 3–5 cm long, in a 250°–300° circumferential pattern around the GEJ, by deploying non-absorbable polypropylene fasteners through the two layers (esopha­gus and stomach) under endoscopic visualization—Fig. 3 [23, 26].
In a systematic review and meta-analysis by the lead author of this review, TIF was associated with a high success rate of 99% and adverse event rate of only 2% [23]. Subjective data based upon the GERD Health-Related Quality of Life (HRQL) score, Gastroesophageal Reflux Symptom Score (GERSS), and Reflux Symptom Index (RSI) as well as objective measures such as DeMeester scores improved significantly post-TIF. Furthermore, PPI therapy was discontin­ued in 89% of patients. Importantly, none of the 32 studies (n = 1475 patients) included in this meta-analysis study included patients with a history of sleeve gas­trectomy. Currently, the role of TIF among patients post–sleeve gastrectomy who
Fig. 3 Representative images of transoral incisionless fundoplication (TIF) device and procedure. Available at: https://www.
endogastricsolutions.com/ tif-procedure/
T. R. McCarty and C. C. Thompson504
report severe GERD-related symptoms remains unclear and an area of needed research. However, given the size of the device, TIF may only be a viable treat­ment for patients with significantly dilated sleeves. While promising results have been shown for non-bariatric surgery patients, more data is needed for patients with a history of sleeve gastrectomy.

9 Conclusion

At this time, there is poor evidence to support the use of any endoscopic modali­ties for the treatment of GERD post-sleeve gastrectomy. We acknowledge there is limited data at this time for endoscopic therapies as a whole. Procedures like
How to Manage Sleeve Complications Through Endoscopy…
505
ARMS, Stretta, and TIF require more data before increased adoption to patients with sleeve gastrectomy. Furthermore, given the paucity of data, future studies are needed to specifically examine this uniquely at-risk population. Given lim­ited data, the use of endoscopic therapy for post-sleeve GERD is driven largely by expert opinion, and limited to centers with expertise. Other laparoscopic pro­cedures, such as the LINX Reflux Management System (Torax Medical, St. Paul, MN, USA) and conversion to Roux-en-Y gastric bypass, should be strongly con­sidered in this patient population. It is important to underscore the mechanisms that contribute to reflux and role of proper surveillance of GERD and Barrett’s esophagus post-sleeve gastrectomy.

References

1. Chiu S, Birch DW, Shi X, Sharma AM, Karmali S. Effect of sleeve gastrectomy on gastroe-
sophageal reflux disease: a systematic review. Surg Obes Relat Dis. 2011;7:510–5.
2. de Jong JR, Besselink MG, van Ramshorst B, Gooszen HG, Smout AJ. Effects of adjust-
able gastric banding on gastroesophageal reflux and esophageal motility: a systematic review. Obes Rev. 2010;11:297–305.
3. Frezza EE, Ikramuddin S, Gourash W, et al. Symptomatic improvement in gastroesopha-
geal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002;16:1027–31.
4. Perry Y, Courcoulas AP, Fernando HC, Buenaventura PO, McCaughan JS, Luketich JD.
Laparoscopic Roux-en-Y gastric bypass for recalcitrant gastroesophageal reflux disease in morbidly obese patients. JSLS. 2004;8:19–23.
5. Woodman G, Cywes R, Billy H, et al. Effect of adjustable gastric banding on changes
in gastroesophageal reflux disease (GERD) and quality of life. Curr Med Res Opin. 2012;28:581–9.
6. Torquati A. Treatment for severe GERD after Sleeve Gastrectomy: conversion to gastric
bypass or endoluminal radiofrequency. https://web.duke.edu/surgery/2015BariatricMasters/
session6_gerd_after_sleeve_torquati.pdf. Accessed 24 May 2020.
7. Braghetto I, Korn O, Valladares H, et al. Laparoscopic sleeve gastrectomy: surgical tech-
nique, indications and clinical results. Obes Surg. 2007;17:1442–50.
8. Braghetto I, Lanzarini E, Korn O, Valladares H, Molina JC, Henriquez A. Manometric
changes of the lower esophageal sphincter after sleeve gastrectomy in obese patients. Obes Surg. 2010;20:357–62.
9. Lazoura O, Zacharoulis D, Triantafyllidis G, et al. Symptoms of gastroesophageal reflux
following laparoscopic sleeve gastrectomy are related to the final shape of the sleeve as depicted by radiology. Obes Surg. 2011;21:295–9.
10. Michalsky D, Dvorak P, Belacek J, Kasalicky M. Radical resection of the pyloric antrum and
its effect on gastric emptying after sleeve gastrectomy. Obes Surg. 2013;23:567–73.
11. Genco A, Soricelli E, Casella G, et al. Gastroesophageal reflux disease and Barrett’s esopha-
gus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complica­tion. Surg Obes Relat Dis. 2017;13:568–74.
12. Yeung KTD, Penney N, Ashrafian L, Darzi A, Ashrafian H. Does sleeve gastrectomy expose
the distal esophagus to severe reflux?: A systematic review and meta-analysis. Ann Surg. 2020;271:257–65.
13. Gagner M, Hutchinson C, Rosenthal R. Fifth international consensus conference: current sta-
tus of sleeve gastrectomy. Surg Obes Relat Dis. 2016;12:750–6.
T. R. McCarty and C. C. Thompson506
14. Kumar N, Thompson CC. Remnant gastropathy due to bile reflux after Roux-en-Y gas-
tric bypass: a unique cause of abdominal pain and successful treatment with ursodiol. Surg Endosc. 2017;31:5399–402.
15. Hathorn KE, Jirapinyo P, Thompson CC. Endoscopic management of gastroesophageal
reflux disease after sleeve gastrectomy by use of the antireflux mucosectomy procedure. VideoGIE. 2019;4:251–3.
16. Inoue H, Ito H, Ikeda H, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease
in the absence of hiatus hernia: a pilot study. Ann Gastroenterol. 2014;27:346–51.
17. Satodate H, Inoue H, Fukami N, Shiokawa A, Kudo SE. Squamous reepithelialization after
circumferential endoscopic mucosal resection of superficial carcinoma arising in Barrett’s esophagus. Endoscopy. 2004;36:909–12.
18. Satodate H, Inoue H, Yoshida T, et al. Circumferential EMR of carcinoma arising in Barrett’s
esophagus: case report. Gastrointest Endosc. 2003;58:288–92.
19. Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled
and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gas­troesophageal reflux disease. Surg Endosc. 2017;31:4865–82.
20. Hopkins J, Switzer NJ, Karmali S. Update on novel endoscopic therapies to treat gastroe-
sophageal reflux disease: a review. World J Gastrointest Endosc. 2015;7:1039–44.
21. Torquati A, Houston HL, Kaiser J, Holzman MD, Richards WO. Long-term follow-up study
of the Stretta procedure for the treatment of gastroesophageal reflux disease. Surg Endosc. 2004;18:1475–9.
22. Crawford C, Gibbens K, Lomelin D, Krause C, Simorov A, Oleynikov D. Sleeve gastrec-
tomy and anti-reflux procedures. Surg Endosc. 2017;31:1012–21.
23. McCarty TR, Itidiare M, Njei B, Rustagi T. Efficacy of transoral incisionless fundoplica-
tion for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy. 2018;50:708–25.
24. Guerron D, Portenier D. A case series on gastroesophageal reflux disease and the bariatric
patient: stretta therapy as a non-surgical option. Bariatric Times. 2016;13(11):18–20.
25. Management of Reflux After Sleeve Using Stretta (MaRSS). U.S. National Library of
Medicine: ClinicalTrials.gov Identifier: NCT02637713. https://clinicaltrials.gov/ct2/show/
NCT02637713. Accessed 24 May 2020.
26. Testoni PA, Mazzoleni G, Testoni SG. Transoral incisionless fundoplication for
gastro-esophageal reflux disease: Techniques and outcomes. World J Gastrointest Pharmacol Ther. 2016;7:179–89.
How to Manage Sleeve Gastrectomy Complications Through Surgery: Gastroesophageal Reflux Disease
Shujhat Khan and Hutan Ashrafian

1 Background

The sleeve gastrectomy (SG) procedure was evolved from the biliopancreatic diversion- duodenal switch procedure in order to reduce complication rates and improve outcomes for patients. The complications can be categorised as early, medium, and long-term. Early complications include gastric leak, bleeding, obstruction, formation of abscess, and infection. Mid-late complications typically include fistula development, stenosis, neofundus, regain of weight, nutritional defi­ciencies and gastro-oesophageal reflux disease (GERD) [13]. GERD is a promi­nent complication that patients will often complain about, and symptoms include chest pain, dysphagia, heartburn, regurgitation, chronic cough, and laryngitis. With the rise in obesity, and the already high prevalence of GERD in these populations, this is a significant cause of morbidity in western populations and is likely set to worsen.

2 Pathophysiology

GERD can be categorised as non-erosive or erosive based on the endoscopic appearance of the oesophageal mucosa. It is particularly important considering the high prevalence particularly in the western countries. Approximately 20%
S. Khan Milton Keynes University Hospital, London, UK e-mail: shujhat.khan15@imperial.ac.uk
H. Ashrafian (*) Institute of Global Health Innovation, Imperial College London, London, UK e-mail: h.ashrafian@imperial.ac.uk
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021 S. Al-Sabah et al. (eds.), Laparoscopic Sleeve Gastrectomy,
https://doi.org/10.1007/978-3-030-57373-7_48
507
S. Khan and H. Ashrafian508
of individuals in USA alone are effected by GERD [4] and, if left untreated, can subsequently lead to the formation of Barret’s oesophagus and adenocarcinoma. There are several mechanisms for the formation of GERD (Table 1). Removal of the gastric fundus and body has consequences on both acid secretion and gas­tric accommodation and shifts the balance between these protective and exacer­bating factors leading to GERD. However, another peak is seen after 6 years, likely caused by incomplete resection of the gastric tissue, thereby leading to a neo-fundus years later [57].
The exact mechanism of GERD in both obesity and post-operatively following SG is unclear [8]. However, one method that has been suggested involves transient relaxation of the lower oesophageal sphincter, which is seen more often in obese patients. This typically occurs following distention of the fundus after a large meal. As a result, these patients experience greater amounts of acid exposure to the distal oesophagus [9, 10].
Additionally, it has been demonstrated that severely obese patients are more likely to present with a motility disorder. This includes a low lower oesophageal sphincter resting pressure, nonspecific motility disorders, and nutcracker oesopha­gus, a diagnosis given to those patients who have a mean contraction amplitude of the lower oesophagus of greater than 180 mmHg. Whilst these features would likely increase the risk of GERD, the majority of these patients were found to be asymptomatic [1113]. Importantly, SG itself can also lead to the develop­ment of GERD in patients following the operation through a separate mechanism. However, it is likely that GERD occurs as a result of a combination of pre-, intra­and post-operative factors.
Our studies suggest approximately 20% of patients who undergo this proce­dure will develop de-novo GERD following a SG whereas approximately 19% of patients will have an increase in reflux symptoms [8]. However, this is likely to be lower than the true value. Indeed, many patients will have GERD but not experience any of the symptoms. In patients who underwent SG, active moni­toring through upper gastrointestinal endoscopy and pH manometry revealed a much higher rate of de novo GERD as well as worsening GERD in those who had pre-existing symptoms [1417]. In addition, patients were found to have a higher rate of oesophagitis, hiatus hernia, as well as Barrett’s oesophagus [1821]. Measuring such complications is difficult simply because many patients won’t
Table 1 Mechanisms for gastro-oesophageal reflux disease in sleeve gastrectomy
Intraoperative causes Poor surgical technique causing strictures Hiatus hernia Opening of the angle of His Smoking Resection of the fundus reducing stomach compliance Dietary factors Damage to vagus nerve Regain of weight Dissection of sling of Helvetius Alcohol
Postoperative causes